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The follow up of patients with non-Hodgkin Lymphomas (NHL) is based on several factors 
including the intention of the treatment and the context in which it is carried out, whether in clinical trials 
or clinical practice. For patients out of clinical trials there seems to be no evidence for the routine use of 
imaging scans or laboratory tests in the follow up after completing treatment(1). 
The clinical history and physical examination are the most important procedures in the monitoring 
of patients after treatment in the clinical practice(1). Nevertheless many physicians indicate serial imaging 
scans or use laboratory markers to guide requests for scans. 
Lactate dehydrogenase (LDH) has proved to be an important prognostic marker and has been incorporated 
in prognostic models of NHL at the moment of diagnosis(2,3); it is also often used in the after treatment follow up. 
In this issue of the Revista Brasileira de Hematologia e Hemoterapia an article entitled “The utility of lactate 
dehydrogenase in the follow up of patients with diffuse large B-cell lymphoma” demonstrates a clear relationship 
between LDH levels 1.5-fold above baseline and the relapse of diffuse large B-cell lymphoma (DLBCL)(4). 
Despite this finding, the authors considered it an inappropriate marker in the follow up of 
asymptomatic patients due to its low specificity and low positive and negative predictive values, which 
would lead to an unnecessary exposure to scans and to increases in cost(4). 
These data seem to be moving in the opposite direction of current technology, when the increasingly 
early and more frequent role of positron-emission tomography (PET-CT) is discussed in the management 
of lymphomas(5). Although this is the most appropriate method in the final assessment and for the 
identification of relapse due to the high negative predictive value, the risk of false positive results as well 
as the risks of excessive exposure to radiation makes its utilization in patient monitoring less interesting(6). 
When we imagine that the follow up of patients with lymphoma submitted to serial tomography 
scans during three to five years of their treatment results in a cumulative dose of over 50 mSv, we note 
that such management has put the patients at risk with the excessive radiation(7). As well as a chance of 
less than 2% of an early diagnosis of relapse(7). 
Faced with these findings, although the use of laboratory tests and scans are extremely widespread in the 
clinical practice of patients with asymptomatic lymphoma and normal physical examination, there is no evidence, 
as of yet in the literature that supports the indication of these complementary exams in the follow up of patients. 
Despite the low cost, LDH has not shown to be a useful exam in the follow up of patients with 
DLBCL in asymptomatic remission(4). Therefore, at present, only the medical history and clinical 
examination are indeed effective in the follow up after the treatment of patients.
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